BRPI0411868A - derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase - Google Patents

derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase

Info

Publication number
BRPI0411868A
BRPI0411868A BRPI0411868-5A BRPI0411868A BRPI0411868A BR PI0411868 A BRPI0411868 A BR PI0411868A BR PI0411868 A BRPI0411868 A BR PI0411868A BR PI0411868 A BRPI0411868 A BR PI0411868A
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
pyrazole derivatives
pyrrol
derivatives active
active
Prior art date
Application number
BRPI0411868-5A
Other languages
English (en)
Inventor
Daniele Fancelli
Barbara Forte
Jurgen Moll
Mario Varasi
Paola Vianello
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BRPI0411868A publication Critical patent/BRPI0411868A/pt
Publication of BRPI0411868B1 publication Critical patent/BRPI0411868B1/pt
Publication of BRPI0411868B8 publication Critical patent/BRPI0411868B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE PIRROL¢3,4-C!PIRAZOL ATIVOS COMO INIBIDORES DE CINASE". A presente invenção refere-se a derivados de pirrol¢3,4-C!pirazol de fórmula I e seus sais farmaceuticamente aceitáveis, como definido no relatório descritivo, processo para sua preparação e composições farmacêuticas compreendendo-os; os compostos da invenção podem ser úteis em terapia no tratamento de doenças associadas com uma atividade de proteína cinase desregulada, como câncer.
BRPI0411868A 2003-07-09 2004-07-08 derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase BRPI0411868B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09
PCT/EP2004/007515 WO2005005427A1 (en) 2003-07-09 2004-07-08 PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Publications (3)

Publication Number Publication Date
BRPI0411868A true BRPI0411868A (pt) 2006-08-08
BRPI0411868B1 BRPI0411868B1 (pt) 2019-11-12
BRPI0411868B8 BRPI0411868B8 (pt) 2021-05-25

Family

ID=34062099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411868A BRPI0411868B8 (pt) 2003-07-09 2004-07-08 derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase

Country Status (41)

Country Link
US (2) US7141568B2 (pt)
EP (1) EP1644376B1 (pt)
JP (1) JP4728232B2 (pt)
KR (1) KR101075711B1 (pt)
CN (1) CN100564380C (pt)
AP (1) AP2214A (pt)
AR (1) AR050045A1 (pt)
AT (1) ATE480540T1 (pt)
AU (1) AU2004255347B2 (pt)
BR (1) BRPI0411868B8 (pt)
CA (1) CA2531759C (pt)
CR (1) CR8171A (pt)
CY (1) CY1110832T1 (pt)
DE (1) DE602004029045D1 (pt)
DK (1) DK1644376T3 (pt)
DO (1) DOP2004000949A (pt)
EA (1) EA009462B1 (pt)
EC (1) ECSP056246A (pt)
ES (1) ES2349780T3 (pt)
GE (1) GEP20084395B (pt)
GT (2) GT200400133AA (pt)
HN (1) HN2004000232A (pt)
IL (1) IL172923A (pt)
IS (1) IS2843B (pt)
MA (1) MA28064A1 (pt)
ME (1) MEP51908A (pt)
MX (1) MXPA06000362A (pt)
MY (1) MY139072A (pt)
NO (1) NO332361B1 (pt)
NZ (1) NZ544514A (pt)
PA (1) PA8606201A1 (pt)
PE (1) PE20050325A1 (pt)
PL (1) PL1644376T3 (pt)
PT (1) PT1644376E (pt)
RS (2) RS20060004A (pt)
SI (1) SI1644376T1 (pt)
TN (1) TNSN06009A1 (pt)
TW (1) TWI343382B (pt)
UA (1) UA81682C2 (pt)
WO (1) WO2005005427A1 (pt)
ZA (1) ZA200600095B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349762T3 (es) * 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
ATE546452T1 (de) * 2003-09-23 2012-03-15 Vertex Pharma Pyrazolopyrrolderivate als proteinkinaseinhibitoren
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
AU2005323797B2 (en) 2005-01-10 2009-07-09 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) * 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
JP5547487B2 (ja) * 2006-11-03 2014-07-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗癌化合物の投与方法
CL2009001158A1 (es) 2008-05-15 2009-10-23 Nerviano Medical Sciences Srl Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
WO2010009985A2 (en) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20110117212A1 (en) * 2008-07-24 2011-05-19 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
KR20140105508A (ko) 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
EP3157921A1 (en) 2014-06-23 2017-04-26 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
CA2989519C (en) 2015-06-15 2023-09-26 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
JP2025511697A (ja) 2022-04-07 2025-04-16 イーライ リリー アンド カンパニー Ｋｒａｓ ｇ１２ｃ阻害剤を作製するための方法
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
EP4547251A1 (en) 2022-06-30 2025-05-07 Eli Lilly and Company Kras g12c inhibitor for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
KR20020060160A (ko) 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
ES2349762T3 (es) 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
AU2002215053A1 (en) 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
CA2434066A1 (en) 2001-01-26 2002-09-12 Pharmacia Italia S.P.A. Chromane derivatives, process for their preparation and their use as antitumor agents
WO2003028720A1 (en) 2001-09-26 2003-04-10 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
CA2493625A1 (en) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
MXPA06000362A (es) 2006-03-28
CY1110832T1 (el) 2015-06-10
IS2843B (is) 2013-08-15
KR20060033001A (ko) 2006-04-18
EP1644376B1 (en) 2010-09-08
US7582628B2 (en) 2009-09-01
GEP20084395B (en) 2008-06-10
TW200510385A (en) 2005-03-16
JP4728232B2 (ja) 2011-07-20
JP2009513525A (ja) 2009-04-02
AP2214A (en) 2011-03-04
NZ544514A (en) 2009-07-31
PE20050325A1 (es) 2005-05-17
IL172923A0 (en) 2006-06-11
PA8606201A1 (es) 2005-08-04
MA28064A1 (fr) 2006-08-01
NO20060113L (no) 2006-04-05
ES2349780T3 (es) 2011-01-11
RS20060004A (sr) 2008-06-05
SI1644376T1 (sl) 2010-11-30
US20050032839A1 (en) 2005-02-10
BRPI0411868B8 (pt) 2021-05-25
KR101075711B1 (ko) 2011-10-21
IS8192A (is) 2005-12-22
IL172923A (en) 2011-09-27
DE602004029045D1 (de) 2010-10-21
ECSP056246A (es) 2006-04-19
PT1644376E (pt) 2010-09-24
RS52155B (sr) 2012-08-31
CR8171A (es) 2006-08-09
ZA200600095B (en) 2007-01-31
US7141568B2 (en) 2006-11-28
BRPI0411868B1 (pt) 2019-11-12
DOP2004000949A (es) 2005-01-15
ATE480540T1 (de) 2010-09-15
NO332361B1 (no) 2012-09-03
AU2004255347A1 (en) 2005-01-20
CA2531759A1 (en) 2005-01-20
GT200400133A (es) 2005-04-18
AU2004255347B2 (en) 2010-04-08
CN1820009A (zh) 2006-08-16
EA200600209A1 (ru) 2006-06-30
DK1644376T3 (da) 2011-01-03
MEP51908A (en) 2011-05-10
WO2005005427A1 (en) 2005-01-20
MY139072A (en) 2009-08-28
TNSN06009A1 (fr) 2007-10-03
TWI343382B (en) 2011-06-11
US20060276471A1 (en) 2006-12-07
GT200400133AA (es) 2007-07-10
CN100564380C (zh) 2009-12-02
EA009462B1 (ru) 2007-12-28
EP1644376A1 (en) 2006-04-12
CA2531759C (en) 2013-04-02
AP2006003480A0 (en) 2006-02-28
AR050045A1 (es) 2006-09-27
UA81682C2 (en) 2008-01-25
HK1089769A1 (en) 2006-12-08
PL1644376T3 (pl) 2011-03-31
HN2004000232A (es) 2011-01-17

Similar Documents

Publication Publication Date Title
BRPI0411868A (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BR0315988A (pt) Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
MY143206A (en) 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
BRPI0507375A (pt) derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
BRPI0508706A (pt) derivados de dicloro-fenil-pirido[2,3-d]pirimidina inusitados, sua fabricação e uso como agentes farmacêuticos
CU23566B7 (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa
UY28409A1 (es) Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden
CU20060152A7 (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: PHARMACIA ITALIA S.P.A. (IT)

Free format text: A FIM DE ATENDER AS TRANSFERENCIAS REQUERIDAS ATRAVES DA PETICAO NO 020110122065/RJ DE 29/11/2011, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO RELATIVO A PRIMEIRA TRANSFERENCIA DEVIDAMENTE NOTARIZADO.

B25A Requested transfer of rights approved

Owner name: PFIZER ITALIA S.R.L. (IT)

B25A Requested transfer of rights approved

Owner name: NERVIANO MEDICAL SCIENCE S.R.L. (IT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2678 DE 03-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.